Share
1,118 Posts.
lightbulb Created with Sketch. 462
clock Created with Sketch. 22/02/25
23:18
Share
Originally posted by Silverchair:
↑
Another Biotech that is financially inferior to Clinuvel but enjoys a valuation 3 times higher after a massive share price jump in the last couple of days following ok results which are about what CUV has been doing year after year. Clinuvel of course with blockbuster near term opportunities the like of which Nanosonics could only dream about - a blockbuster phase 3 trial with an ALREADY FDA approved drug for example that is already producing superior profits to NAN just on a small indication. An Ozempic potential real tanning photocosmetic announced in their Bulletin for next year. This comparison is Nanosonic's first half year results just released to CUV's full year results from 6 months ago for an interesting side by side valuation. I can see why Jefferies just put a $39.20 price target on CUV, they definitely look undervalued with their P/E approaching 10 (with cash removed) compared to NAN with a huge P/E of ~ 110. Nanosonics : Revenue 1HY2025:$93.6 Million (up 18%) Profit after tax. $ 9.8 M CASH ON HAND $145 MILLION Clinuvel (CUV) Revenue FY2024:$95 Million (up 15%) Net Profit after tax FY2024: $35.6M (profit) CASH ON HAND $200 MILLION and growing all the time All IMO DYOR
Expand
it doesn’t seem fair. Is there someone we can complain to?
